Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | MC3R | P41968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4302305 | 0.95 | CYP4F2 (0.43) | CYP4F2CYP4A11MMP12OPRM1CYP1A2 | |
| SCHEMBL1166333 | 0.87 | ALDH1A1 (0.39) | CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10204398 | 0.84 | ALDH1A1 (0.45) | CYP1A2CYP3A4MRGPRX4SMYD3 | |
| SCHEMBL4307516 | 0.83 | PARP1 (0.45) | CSF1RIGF1RLOXL2SMYD3 | |
| SCHEMBL4944793 | 0.83 | ALDH1A1 (0.38) | CYP4F2CYP4A11CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28728220 | 0.82 | GABRA1 (0.43) | CYP1A2 | |
| SCHEMBL30341012 | 0.81 | CYP4F2 (0.50) | CYP4F2CYP4A11MMP12OPRM1CSF1R | |
| SCHEMBL4941679 | 0.81 | PARP1 (0.46) | CYP4F2CYP4A11CSF1RLOXL2SMYD3 | |
| SCHEMBL31391294 | 0.79 | CDC7 (0.34) | CYP4F2CYP4A11MRGPRX4SMYD3TSHR | |
| SCHEMBL4937449 | 0.78 | LOXL2 (0.46) | CYP4F2CYP4A11CYP1A2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| WO-2010054764-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1891047-A4 | 1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1891047-A2 | 1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer HealthCare AG (DE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1765811-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006133006-A2 | 1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE AG (DE) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006023707-A2 | 2-AMINOTHIOPHENECARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006002383-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | HIF1AN, HIF1A, VHL | CYP4F2 417/4885CYP4A11 449/4885MMP12 1240/4885 |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | CYP4F2 305/4885CYP4A11 2087/4885MMP12 4696/4885 |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | MCL1, HDAC5, HDAC6 | CYP4F2 4269/4885CYP4A11 4771/4885MMP12 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.